Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jonathan F, Khan"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3ad3fa8069f04262bcf6620c2f1d103e
Autor:
Jedd D Wolchok, Taha Merghoub, Sadna Budhu, Roberta Zappasodi, Svena Verma, Inna Serganova, Lauren Dong, Levi Mark Mangarin, Yacine Marouf, Jonathan F Khan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f5d34c96234c445483351b5b93532dde
Autor:
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey, Andrea V. Lopez, Metamia Ciampricotti, Charles M. Rudin, Renier J. Brentjens
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 9 (2023)
Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor-specific cel
Externí odkaz:
https://doaj.org/article/1add364070234a5a9f42731c9c6e16d1
Publikováno v:
Progress in molecular biology and translational science. 164
CAR T cell therapy of cancers promises to revolutionize oncology by harnessing the powers of synthetic biology and immunotherapy in a single agent. CARs are synthetic receptors composed of an extracellular antigen binding domain and one or more intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::059cfe837510e7c8aeb1330ac4e7c4d0
https://pubmed.ncbi.nlm.nih.gov/31383408
https://pubmed.ncbi.nlm.nih.gov/31383408
CAR T cell therapy of cancers promises to revolutionize oncology by harnessing the powers of synthetic biology and immunotherapy in a single agent. CARs are synthetic receptors composed of an extracellular antigen binding domain and one or more intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d20b1bec0296be273ea4578bc271de60
https://doi.org/10.1016/bs.pmbts.2019.07.004
https://doi.org/10.1016/bs.pmbts.2019.07.004
Autor:
Brendan Lichtenthal, Jonathan F. Khan, Jacob G. Vineberg, Joshua D. Seitz, Longfei Wei, Chi-Feng Lin, Iwao Ojima
Novel tumor-targeting drug conjugates, BLT-F2 (1) and BLT-S-F6 (2), bearing a fluorotaxoid as the warhead, a mechanism-based self-immolative disulfide linker, and biotin as the tumor-targeting module, were designed and synthesized as 19F NMR probes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba63700ff355068d317789bc8057cc53
https://europepmc.org/articles/PMC4337250/
https://europepmc.org/articles/PMC4337250/